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RESEARCH SUMMARY 
 
 
In silico methods can be applied in many ways to partly replace, complement or render more efficient experimental 
approaches to drug design. In this thesis, computational approaches were employed to: 
- Determine physico-chemical differences between the binding sites of two related proteins, human ARTD-1 and 
ARTD-2, taking into account the intrinsic flexibility of these enzymes as observed by molecular dynamics simulations; 
- Based on molecular dynamics simulations, identify protein conformations falling within densely explored 
regions of phase space (“energetically-favourable” basins of kinetically clustered conformations) of ARTD-1 that present 
physico-chemical differences relative to ARTD-2 for use in a high-throughput in silico docking campaign; 
- Define a scoring function to apply to small-molecule compound poses within the ARTD-1 binding site with the 
aim of enriching the fraction of high binding affinity compounds of a library above a selected score cut-off;  
- Propose for experimental validation small-molecule compounds binding ARTD-1 with putative high affinity and 
forming selective interactions with the ARTD-1 binding site not available to be formed with ARTD-2; 
- Generate a homology model of human macrodomain-containing protein 2 (MacroD2), to identify residues in 
MacroD2 putatively forming interactions with analogues of a newly-identified endogenous ligand and to detect stable 
water molecules in the MacroD2 binding site as observed in molecular dynamics trajectories of the explicitly solvated 
protein-ligand complex. 
Further, in vivo methods were used to determine the values of pharmacokinetic parameters and to establish tumor 
growth inhibition efficacy of small-molecule inhibitors of multiple tyrosine kinases identified as cytostatic on a subset 
of immortalised human cancer cell lines. 
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ZUSAMMENFASSUNG 
 
 
In-silico-Methoden können angewandt werden, um experimentelles Drug Design zu komplementieren oder teilweise 
zu ersetzen. In dieser Doktorarbeit wurden computergestützte Methoden verwendet um: 
- physikalisch-chemische Unterschiede zwischen den Bindungsstellen ähnlicher Proteine - dem humanen ARTD-1 und 
ARTD-2 - zu bestimmen, wobei die Dynamik dieser Unterschiede (aus  Molekulardynamiksimulationen)  berücksichtigt 
wurde; 
- mit Molekulardynamiksimulationen energetisch günstige Proteinkonformationen von ARTD-1 zu bestimmen. Diese 
Proteinkonformationen können unter Berücksichtigung der zuvor berechneten physikalisch-chemische Unterschiede 
zwischen ARTD-1 und ARTD-2 für die Anwendung in in-silico-Docking weiter selektiert werden; 
- eine Scoring-Funktion für die Bewertung kleiner Moleküle an der ARTD-1-Bindungsstelle zu definieren, mit dem Ziel, 
hoch-affine Binder aus eine in-silico Bibliothek zu identifizieren; 
- neue Moleküle, die ARTD-1 aber nicht ARDT-2 binden sollten, auszuwählen, um diese dann experimentelle validieren 
zu können; 
- ein Homologie-Modell des menschlichen Makrodomain-Proteins 2 (MacroD2) zu erstellen; um Reste in MacroD2 zu 
identifizieren, die wahrscheinlich mit Analogen eines neu bestimmten endogenen Liganden interagieren, und um 
stabile Wassermoleküle an der MacroD2-Bindungsstelle zu ermitteln, wie sie in Molekulardynamik-Trajektorien des 
Protein-Ligand-Komplexes (in wässriger Umgebung) beobachtet wurden. 
Weiters, Pharmakokinetische Parameter von Tyrosin-Kinase-Inhibitoren, sowie deren Potential Tumorwachstum zu 
hemmen, wurden in-vivo bestimmt. 
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1. INTRODUCTION 
1.1. DRUG DEVELOPMENT PROCESS 
This introduction navigates from large to small scales along the drug development process. This is undertaken prior to 
delving into the application of in silico (computational) atomic-level studies to a drug development goal, to define the 
achievable scope and limitations of these studies relative to a human-level objective.  
It is not possible to define a unique development process leading to a drug for human use. Until very recently since the 
advent of disease treatment by xenobiotics, compounds presenting therapeutic benefits were largely identified from 
natural products based on observations following their administration to patients made outside of a controlled trial 
situation, and without understanding their mechanisms of action. These natural products originated from organisms 
having sometimes evolved to produce compounds in response to a similar threat [1]; through human experimentation, 
such compounds occasioned to meet the right indication enough to be identified as a treatment.  
This process has significantly evolved in line with molecular-level gains in understanding disease mechanisms. In recent 
decades, identification of a drug target, an aberrantly acting or expressed biomolecule (or its upstream/downstream 
partners) has defined the first step of projects aiming to identify compounds modulating this aberrancy. Many such 
targets have been proteins with a role in cellular signal propagation, whose over-signaling is associated, for example, 
with amplified growth rates characteristic of cancerous cells. Such so-called “translational research” projects (depicted 
in Fig. 1) follow the selection of the protein target by a campaign to find small-molecule compounds (“hits”) binding this 
target with high potency and preventing it from overactive function, often by excluding the proteins’ endogenous 
substrate [2]. In most cases, these hit compounds are then modified (“derivatised”) to optimise potency and the 
selectivity of binding to the intended over other targets. Later derivatives meet further downstream requirements: 
resistance to cellular efflux, aqueous solubility, cell permeability, metabolic stability, minimal toxicity and most 
importantly, measurable modification in disease phenotype in a model system (cellular or animal) thought to be 
reflective of an expected phenotypic change at the level of the human organism. 
Figure 1. Translational research-based drug development process 
If the preclinical evidence collected in model systems is persuasive, clinical development in humans may follow, 
commencing with minimal toxicity dose range determinations and proceeding to efficacy studies in groups counting 
dozens and then hundreds of patients, with comparisons to conventional therapy. Compelling results and the economic 
potential the drug compound may see it become a standard treatment. 
Introduction 
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In silico studies have potential roles to play throughout this process (the reader is directed to [3]). In the following, focus 
is lent to their preclinical usage, notably to identify compounds binding with high affinity to a preselected target. The 
discussion includes mention of steps upstream and downstream from this identification step, as their outcomes may 
influence the success of computational undertakings. 
 
1.1.1 TARGET IDENTIFICATION 
A therapeutic target is a biomolecule whose activity has the potential to be modified by an applied (generally xenobiotic) 
substance resulting in a desired phenotypic change at the level of the cell and, ultimately, organism. The instant discussion 
will center on the protein class of therapeutic targets, and more particularly on enzymes, which catalyze the conversion 
endogenous substrates to products. 
The enzymatic proteins of this thesis convert small-molecule substrates to products covalently bonded to recipient 
proteins, or act to remove these. Such products constitute a post-translational modification (PTM) of the recipient; 
these PTMs can serve to direct the modified protein to perform a new function affecting cellular phenotype [4]. Over-
activity of enzymatic proteins may result in modification of cellular phenotype to an extent that it contributes to or 
drives disease. Indeed, the definition of a therapeutic target includes both disease phenotype “drivers” (whose 
modulation may resolve the disease) and “passengers” (whose modulation may alleviate disease symptoms). 
Two approaches have principally been used to identify potential drug targets. In so-called “top-down” approaches, all 
cellular processes and interaction networks known to be solicited in generating a disease phenotype constitute the 
starting set from which a target is identified. By contrast, “bottom-up” approaches examine common genetic or 
proteomic variants observed in the context of a disease to identify putative targets [5]. 
A potential target is preliminarily validated (generally by loss- or gain-of-function studies [6, 7]) in model systems, such 
as a cell or animal. A major hurdle is then to define a suitable model that recapitulates the human disease mechanism, 
its role in generating a measurable phenotype (or a marker of this phenotype), and extent-appropriate changes in 
phenotype on perturbations of the system.  
Implication in disease phenotype is not sufficient to define a therapeutic target. This target must further be capable of 
interaction with a xenobiotic such that its activity is modulated in the direction of restored health. Proteins with such a 
capacity are called “druggable” [8]. Principally, these xenobiotics are in the form of a small-molecule compound or 
antibody. In the case of small-molecule drugs, binding is usually to a cavity on the protein surface, and facilitated by 
electrostatic, -orbital stacking and van der Waals interactions. 
Identification of novel therapeutic targets is clearly challenged by the use of abstracted target validation models and 
the need for druggability prediction; moreover, there is a risk that the target acts in a redundant cellular process to 
generate the phenotype, a fact which may only later become apparent when the true biological system circumvents the 
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drug-driven change by activating redundant pathways to generate the disease phenotype. As per Medina-Franco, 
“[d]rug design at the single molecular target level ‘is blind’ to other processes that are inevitably connected through 
complex networks with higher levels of the hierarchical nature of biological systems” [9].  
Therefore, evaluation of outcomes of a drug development campaign should include a review of its shortcomings. Failure 
to identify the correct target or indeed targets that must be (simultaneously) modulated to modify a disease phenotype 
does not imply failure in the approach of designing target-selective drugs [10]. The future may well lie in the use of drug 
cocktails composed of potent therapeutics each modulating its own validated target among a target set.  
 
1.1.2 SMALL-MOLECULE HIT COMPOUND IDENTIFICATION 
On the assumption that a valid therapeutic target has been identified, the first objective according to Fig. 1 is to find a 
series of small-molecule “hit” compounds binding a specified region of the target with high affinity such that it brings 
about the desired change in target protein function. We consider the case of a xenobiotic small-molecule ligand 
reversibly binding an enzymatic protein at the binding pocket of the endogenous substrate. By excluding the substrate, 
this competitive ligand decreases the rate of formation of the endogenous product; the function of this enzymatic 
protein is thereby effectively modulated. 
Figure 2. Enzyme kinetics relative to an endogenous substrate, product and xenobiotic ligand 
With reference to Fig. 2, which assumes negligible return of product to substrate, this modulation can be discussed 
quantitatively. In absence of ligand (L ) and assuming a non-limiting rate of product release from the complex, the 
enzymatic function of the protein at equilibrium is characterised by the rate of generation of product,v .  
 
    / catv d P dt k ES    
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The first step of the reaction (substrate binding) is assumed to reach equilibrium such that the ratio of reactants to 
products is constant: 
Product generation per unit time is then proportional to the concentration of “free” enzyme,  E  available to act on 
the endogenous substrate. As per Fig. 2, the xenobiotic ligand effectively sequesters the enzyme, lowering the 
concentration of free enzyme available to the endogenous substrate. The free enzyme in presence of the xenobiotic 
ligand is then    E EL . 
We define 
iK  of the xenobiotic ligand (“ i ” for inhibitor of enzymatic function) at equilibrium as: 
To decrease the value of v , the fraction of enzyme complexed by the ligand at equilibrium can be maximised by two 
routes: increasing the ligand relative to enzyme and substrate concentrations, and by decreasing the value of 
iK , a 
measure of the inherent binding affinity of the ligand for the enzyme. Because of the risk that xenobiotics generate an 
unwanted and deleterious (“toxic”) phenotype or have metabolites doing the same (this risk often being heterogeneous 
in a patient population and difficult to predict) [11], it is generally an objective to limit the amount of ligand administered 
to patients. Accordingly, the focus is turned to identifying compounds having a high binding affinity (low 
iK ) for the 
target. It is to be remarked, however, that compounds established as non-toxic over a wide dose range do not need as 
high a binding affinity for their target as generally sought for novel xenobiotics. This motivates the repurposing of drugs 
having established safety in humans a modulators of different targets. 
The value of 
iK  can be obtained experimentally; the rate of product generation (or substrate disappearance) is 
measured at fixed total enzyme concentration and varying substrate concentrations, and plotted as Fig. 3. 
 
Figure 3. Reaction speed as a function of substrate concentration in the absence and presence  
of a substrate-competitive, reversibly-binding ligand 
  
 
,
,
off L
i
on L
k E L
K
k EL
 
  
 S
E S
K
ES

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At low substrate concentration, the reaction rate varies near linearly with  S . The asymptote corresponds to the 
maximum velocity, 
maxV , when all enzymes substrate-bound. On reaching maxV , the rate of enzymatic activity is no 
longer limited by recruitment of substrate to the enzymatic binding site; it only depends on the rate of conversion of 
enzyme bound ligand to product 
catk . This is described by the Michaelis-Menten equation: 
 where  ,
,
off S cat
M
on S
k k
K
k

   
  max 0catV k E   
MK  is the Michaelis-Menten constant. It corresponds to the substrate concentration at which ½ maxV  is reached. 
Accordingly, a small value of 
MK  indicates that only small amounts of substrate are required to saturate the enzyme. 
Although 
MK  is obtained from the above plot generated at a given enzyme concentration, it is invariant to this 
concentration and enzyme-substrate pairs has a single characteristic 
MK  (at a given pH and temperature). Interestingly, 
physiological substrate concentrations are often close to their target enzyme 
MK  value; near to MK , small changes in 
substrate concentration translate in large effects on enzymatic rate, attesting to the finely-tuned response systems that 
enzymes represent. 
iK  is determined by the same assay as MK , but in the presence of a set ligand concentration. Recasting the Michaelis-
Menten equation, one obtains a Lineweaver-Burk Plot in presence and absence of a ligand.  
Figure 4. Lineweaver-Burk plot to determine 
MK and 
app
MK  
As per the above figure, the presence of ligand leads to the measure of an “apparent” 
MK  (
app
MK ), differing from that 
obtained in absence of ligand. The enzyme-substrate 
MK can be factored out of 
app
MK  as follows to obtain the value of
iK .  
 
 
 
 max M
S
v V
S K


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app
M MK K  
 where 
 
1
i
I
K
     
Like 
MK , iK  is invariant to substrate and enzyme concentrations used in its determination. Provided then that 
experiments are run at the same pH and temperature (and indeed these are often set to match their narrow 
physiological values), 
iK  values of different ligands can in principle be compared to one another (nonetheless a 
discussion of the errors in their measurement follows). Alternatively, enzyme inhibitors can be characterised by their 
inhibition concentration (
50IC , at which enzyme rate is reduced to 50% of maxV ) determined in experiments fixing both 
enzyme and substrate concentrations, while varying the concentration of inhibitor. The 
50IC value obtained depends on 
the substrate concentration employed, and 
iK  and 50IC are related by the Cheng-Prusoff equation. 
where  S  is the substrate concentration of 50IC determination and MK  the constant of that substrate-enzyme pair. 
50IC  values are often determined at substrate concentrations near MK , where the change in rate per unit of substrate 
concentration is largest. Indeed, 
50IC values collected from a large database relative to different proteins and measured 
by different research groups were found to differ from 
iK  values by a factor of 2 to 2.3 [12], attesting to the general 
usage of such substrate concentrations by experimentalists. 
It is worth underlining here that whereas Fig. 3-4 refer to experimental outcomes, Fig. 2 is presented as an underlying 
model. Already, we note that this model is highly simplified. Proteins are dynamic structures that explore a set of 
conformations within the environment of the human body [13]; protein-ligand complexes often present an adapted 
conformation allowing enthalpically-favourable intermolecular interactions [14]. If the set of protein conformations 
observed in the complex are not among those frequently adopted by the apo protein, there may be a time- or energetic-
barrier to adopting this new conformation. As such, the model of complex formation might be adapted as in Fig. 5, 
which presents two theories of protein conformation adaptation relative to protein-ligand complex discussed in 1.2.1. 
From the foregoing discussion, the reader should retain that high binding affinities (low
iK or 50IC ) can be quantified 
and are desired to limit the unknown risk of ligand-associated toxicities. As we move to in silico methods to identify 
putative high-affinity ligands, we have already alluded to a challenge in doing so; effective screening for ligands will have 
to take into account possible conformational variants of the target protein. 
 
 
50
1
i
M
IC
K
S
K


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Figure 5. Enzyme kinetics relative to a xenobiotic ligand with conformational variation of the enzyme, from [15] 
 
1.1.3 SMALL-MOLECULE HIT-TO-LEAD DERIVATISATION 
Following hit compound identification, addition or modification of its chemical moieties may be undertaken to improve
50IC or iK values. To allow for such modifications while limiting molecular weight, it is advantageous for hits to have a 
high ligand efficiency (
iK  normalized by ligand heavy atom count or molecular weight) [16]. A crystal or NMR structure 
of the hit complexed with its target protein is helpful to identify where modifications or additions can be made. The 
selectivity, characterised by a series of ratios of ligand 
iK  of each unintended over intended target, may also be 
improved at this stage by modification leading to selective interactions that are unique to the target binding site (the 
reader is directed to [17]). Additionally, changes may be made to affect aqueous solubility [18], and to replace moieties 
known to be toxic [19] or metabolised [20]. 
Once a compound with sufficient potency and selectivity is found, it will generally be evaluated in a model system of 
the disease. In the case of cancer, this model system may be immortalised or patient-derived tumor cells growing in a 
dish. The latter can offer the advantage of more closely reflecting their biochemical makeup of origin (though both will 
differ due to culturing outside of the tumor environment; Domcke [21], for example, reports on differences in gene copy 
number, mutations and mRNA expression profiles of ovarian cancer cell-lines relative to patient tumor samples). In 
analogy to 
50IC determinations on the target enzyme, measures of cell viability (such as by MTT assay, [22]) over a dose 
range of compound provide a concentration causing 50% of cells to lose (metabolic) viability. 
 
1.1.4 SMALL-MOLECULE COMPOUND IN VIVO EVALUATION 
Despite the successful identification of small-molecule compounds binding their target with high affinity and 
demonstrating activity in cellular disease models, compounds often lack efficacy in animal models (“in vivo”). In vivo 
efficacy requires that (a) sufficient compound reach its target biomolecule and (b) that this biomolecule remains critical 
to the extent of disease phenotype in the in vivo environment.  
Introduction 
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The preference for oral over caregiver-administered drug delivery carries a risk of systemic drug concentrations being 
limited by inefficient absorption through the intestinal wall. On reaching the systemic circulatory system, drug is 
distributed throughout the body and to be effective, it must reach its target location; the extent of distribution among 
the compartments of the body will often depend on the lipophilic and hydrophilic properties of the compound. The drug 
may be metabolised into inactive products, reducing the effective drug concentration (though metabolic pathways have 
been used to the advantage of the prodrug strategy), and/or excreted from the body before bringing about the desired 
phenotypic change. Insights into ADME (Absorption, Distribution, Metabolism and Excretion) of a xenobiotic are often 
gained through evaluation of pharmacokinetic parameters in animal models, in part based on metrics derived from the 
evolution of xenobiotic concentration in blood plasma over time.  
 
Figure 6. Pharmacokinetic evaluation in mice relative to compound 11d of [23] 
Right-hand panel pictorially represents the study design leading to the curve of compound concentration in blood plasma over time 
given in the left-hand panel. 
 
Useful metrics include the area-under-the-curve ( AUC ) of blood plasma compound concentration over time, from 
which a number of further parameters are calculated, such as oral bioavailability ( %F , fraction of orally administered 
compound reaching the systemic circulation unchanged), compound elimination half-life (t½) and maximum compound 
concentration following oral exposure (Cmax).  
The second efficacy requirement is that the target remain relevant to the extent of disease phenotype in vivo. Cellular 
networks and processes may be differently established and activated by the three-dimensional vascularised 
environment of multicellular organisms. To this end, relatively poor model systems exist to recapitulate the future 
human environment for efficacy evaluations [24,25]. Nevertheless, animal model studies are useful in that they better 
reflect the drug-response of a disease than a dish of cells. For this reason, regulatory authorities will often require animal 
models studies, which in the case of cancer, are often partly based on the measure of tumor growth inhibition in a 
mouse implanted with human tumor cells. 
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Figure 7. Tumor growth in a xenograft mouse model treated with a therapeutic compound (11d) and vehicle-control [23] 
 
Lastly, in vivo studies often provide the first evaluation of toxicity: the negative effects of xenobiotic compound (and 
their metabolites) binding to target and non-target biomolecules in a diversity of healthy cells. This merits a brief word 
on the identification of targets in view of not efficacy, but toxicity: in some cases, a disease phenotype is associated with 
overexpression of a given biomolecule. If returning biomolecule concentrations to normal levels leads to a decrease in 
extent of the undesired phenotype, this biomolecule may be considered as a candidate for targeted therapy. Yet it is 
important to ensure that this target is not expressed and required for cellular viability within all or even a subset of 
healthy cells critical to well-being. Indeed, if cellular uptake is assumed comparable over all cells, it is clear that a greater 
fraction of normally expressed target in healthy cells will be sequestered at a given concentration of ligand than 
overexpressed target in disease-causing cells. The consequent extent of healthy cells death may outweigh the benefits 
of returning diseased cells to a healthier phenotype. Yet in line with this concept, a recent publication [26] has 
underlined a promising new approach aiming at the “Achilles heel” of cancers: targeting essential gene products that 
are uniquely under-expressed in cancer cells. 
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1.2 APPLICATION OF IN SILICO METHODS TO PRECLINICAL DRUG DEVELOPMENT 
If in silico methods are used in drug design, they must be equivalent to or advantageous over available experimental 
methods. Such advantages might reside in: 
- Time- or cost-efficiency in achieving a given goal; 
- Capacity to achieve a given goal. 
High-throughput virtual screening was used in this thesis relative to two objectives: 
- To define a scoring function to apply to small-molecule compound poses within the ARTD-1 binding site with the 
aim of enriching the fraction of high binding affinity compounds of a library above a selected score cut-off;  
- To propose for experimental validation small-molecule compounds binding ARTD-1 with putative high affinity and 
forming selective interactions with the ARTD-1 binding site not available to be formed with ARTD-2. 
The following discussion considers the search for small-molecule drugs competing with the endogenous substrate to 
reversibly bind an enzyme. As in the experiments discussed previously, in silico approaches “expose” the target protein 
to a compound and a signal is read as a measure of binding affinity. The wet lab experiment requires no knowledge of 
the conformational ensemble of the protein-ligand complex established in the test environment; it does require a 
physical sample of each member of the library for testing. By contrast, no physical samples are needed for in silico 
evaluations, underlining their interest for large libraries and highly novel compounds. Knowledge of protein 
conformation(s) may, however, be determinant to in silico success. 
To identify potent ligands from a ligand library, a set of conformations (“poses”) of each ligand in the target site of the 
protein is generated and must include at least one representative of the true ensemble of conformations adopted by 
the corresponding protein-ligand complex. This or these representative(s) then need to be extracted from the generated 
set and ranked relative to representative poses of the protein with the remaining ligands of the library. This ranking 
should distinguish ligands having high binding affinity from the rest. 
If a high-performing combination of docking algorithm and ranking (“scoring”) function can be found, in silico screening 
offers advantages of speed and diversity of evaluated compounds over wet lab methods. Prior to any compound 
synthesis or evaluation, complexes may be selected or eliminated based on their particular protein-ligand interactions, 
offering the possibility to favour compounds forming selective interactions that are unique to the target, and to avoid 
interactions with residues known to undergo drug-induced resistance mutations in vivo.  
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1.2.1 DOCKING 
The first requirement, the generation of an ensemble of ligand poses in the protein binding site that includes a 
representative of the true complex, is partly an issue of algorithms. In general, the conformation of the protein is 
approximated as fixed and originates from crystal, NMR, homology-modelled or molecular dynamics-generated 
structures. For the purpose of speed, the only degrees of freedom during docking are rotations about ligand dihedral 
angles. Retained poses are those in which the ligand “fits” the protein binding site without excessive steric clashes 
between their atoms represented as spheres. But even an exhaustive search of ligand conformations within the binding 
site will not generate a representative of the true complex if the rigid protein structure is incorrect. As per McCammon 
[27]: “Virtual screening results are influenced by the PDB structure chosen for screening because the fit of individual 
ligands in the pocket is affected by even the most minor structural changes”.  
Indeed, proteins are not rigid structures, and they often present alternative conformations to their apo structure when 
complexed with a ligand, as evidence by crystal and NMR investigations. To partly account for these alternative 
conformations, the docking campaign can include a set of rigid conformations of the protein (for “ensemble” or 
“conformational docking”). This invites the question of how to generate and select this set. 
While experimental evidence lays plain the existence of differing protein conformations in apo and complexed 
structures, they have not conclusively revealed the process of this conformational change. Accordingly, hypothetical 
models to fit experimental observations have been proposed and currently at least two are in circulation: in the 
“induced fit” mechanism [28], the ligand binds a protein conformation from among an ensemble of protein 
conformations that does not include that of the complex. Subsequent to or concurrent with ligand binding, the protein 
“responds” to the ligand by effecting a conformational change to reach a new state maximising the favourable free 
energy change of complex formation. By contrast, conformational selection hypothesizes that the ligand “selects” (binds 
to) a protein conformation that pre-exists within the apo protein conformational ensemble. As per Valente [29]: “In the 
free state, protein regions displaying conformational diversity exhibit equilibria among pre-existing conformations. In 
the presence of a ligand, one of these conformations is stabilized, so that the ligand does not need to induce a new 
conformation. Upon ligand binding there is a population shift toward the bound conformational state. Conformational 
diversity of binding sites of several proteins has been measured and has important practical as well as thermodynamical 
consequences: binding sites can be mapped without prior knowledge of the ligand and also evolution of binding sites 
depends mostly on the free state, occurring at least partially independently of the ligand”. The last part of this 
concluding sentence hints at a third hypothesis: that the process involves a mixture of both mechanisms, with ligand 
Introduction 
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selection of a protein conformer “near to” that of the complex and some mild structural adaptations of the protein (and 
ligand) thereafter.  
Figure 8. An overview of the free energy landscape, conformational selection and population shift from [30]. 
For the purpose of in silico docking to rigid protein structures, the conformational selection hypothesis invites 
alternative apo protein conformations be taken into account and indeed hints at the use of molecular dynamics 
techniques to generate a conformational ensemble. But which ensemble members should be included in the docking 
campaign? One might select a set of MD-generated protein conformations based on maximising their structural 
diversity. Yet this could lead to the inclusion of protein conformations corresponding to rare, high-energy states. 
This is intuitively (though not definitively, see [31]) unsatisfying because although ligand binding may change the energy 
landscape of a protein to stabilise a given protein conformation, it must be to an extent that the free energy of the 
complex is lower than that of the free protein and ligand, as well as the free energy of the protein-endogenous substrate 
complex and all alternative protein-ligand complexes: commencing from a high free energy protein conformation 
implies a significant stabilization through ligand binding is necessary. Though this is not impossible, it suggests a rare 
ligand binding with exceptional binding affinity.  
For this reason, a diversity of states among those of the highly-populated free energy basins, and not barriers, of MD 
simulations of the apo protein were selected for the docking projects presented herein. This position is supported by 
the following excerpt [32] regarding two targeted small-molecule therapeutics, Dasatinib and Imatinib: “Dasatinib is 
~350 times more potent an inhibitor of the Abl kinase than imatinib. Dasatinib recognizes the active conformation of 
the kinase domain, which is likely to be the predominant form in cancer cells. One reason, therefore, for the higher 
affinity of dasatinib for Abl is due to its not having to stabilize a less populated conformation.”  
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1.2.2 SCORING 
Following docking and the generation of sets of protein-ligand complexes presumed to include a representative of their 
true conformation, it is necessary to extract this representative and compare it with representative complexes of other 
ligands according to an estimation of binding affinity.  
According to thermodynamics, spontaneous complex formation from its separate parts occurs with a decrease in free 
energy ( 0bindingG  ). Consistent with this for complex formation at equilibrium: 
where 8.314 J
mol K
R

   
As 
iK  decreases and the ligand binds the protein with higher affinity, bindingG  becomes more negative and complex 
formation more favorable. For completeness, it is mentioned here that 
bindingG  or ( )bindingG   between two complexes 
with two (preferably similar) ligands may be evaluated by molecular dynamics-based techniques of thermodynamic 
integration and free energy perturbation. Both are computationally demanding and hence incompatible with 
evaluations of complexes formed with large ligand libraries. We therefore need an estimator of 
bindingG  ( bindingG

 ); 
this estimator can include any term and its equation can take on any form, provided that it correctly reproduces 
experimental values. 
 
Decomposition of free energy 
Free energy changes can be decomposed into contributions of enthalpic and entropic changes on binding: 
Changes in entropy of the solute on binding are presumed to be both unfavorable to 
bindingG , consequent to restriction 
of ligand and protein conformational freedom. In contrast the release of structured water from the binding site and 
ligand is favourable. The extent of entropy change is challenging to estimate relative to a static picture of system 
components: nonetheless, we note that the conformational entropy change on binding tends to be unfavorable with 
increasing ligand rotatable bonds (due to loss of torsional entropy), and that decreases in solvent accessible surface 
area (SASA) of both the ligand and protein with binding include liberation of structured water surrounding hydrophobic 
regions, increasing 
bindingS .  
Intramolecular protein-ligand interactions consistent with hydrogen bonds, salt bridges, van der Waals interactions and 
-orbitals stacking, among others, are apparently throughout crystal and NMR structures of complexes. Their formation 
is exothermic and (to the extent that they are more favorable with each other than with water) they decrease system 
enthalpy, 
bindingH , on binding (the reader is directed to the following perspective article on molecular interactions 
, ln( )binding eq iG RT K 
binding binding bindingG H T S   
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[33]). Many such interactions can be modeled as a function of inter-atom distance by equations of charge (Coulomb) 
and van der Waals (Lennard-Jones) interactions, as presented in the empirical potential energy forcefield discussion 
hereafter. 
 
Linear interaction energy 
The above discussion provides one possible selection of terms for bindingG

 . In building a mathematical model, which 
terms should be included and how should they be combined? One possibility issues from the semi-empirical LIECE 
(Linear Interaction Energy (LIE)[34] with Continuum Electrostatics) method [35], which is based on the linear 
combination of van der Waals and electrostatic terms (evaluated using an implicit solvent model and calculated with 
CHARMM using the Poisson equation solved numerically by the finite-difference method for determination of the 
electrostatic component of solvation energy [36,37]). Each term is evaluated as the difference between end points of 
the thermodynamic cycle of ligand binding, i.e. the bound and free states [38], and weighted to fit experimentally-
derived values of 
bindingG .  
 
Solvation effects: Finite difference Poisson equation 
As the electrostatic component of solvation energy was also considered in the model of a project of this thesis, a brief 
explanation of the Poisson equation and its resolution is provided here. In a continuum solvent model, all solute atoms 
are considered explicitly as point-charged particles having a low dielectric constant (i.e. low ability to polarize in 
response to an external electric field; generally in the range of 2-4 for proteins and small-molecules), while the solvent 
is implicit and represented by its dielectric constant (~80 in bulk water, where a high value reflects a high ability to re-
orient water molecule dipoles and thus optimise interaction with an electric field). The electrostatic potential at a given 
point in space (ϕ(r)) is dependent on solute’s charge density (ρ(r)) and the local dielectric ((r)) according to the Poisson 
equation: 
On immersion of a solute (here protein or small-molecule) in solvent, induced charges appear at their boundary due to 
the difference between solute and solvent dielectrics, locally modifying the dielectric from the bulk values. The 
electrostatic potential is generally determined relative to points on a grid applied to the solute-solvent system (where 
each grid point is assigned a charge and dielectric based on those in proximity) according to the finite difference method. 
The electrostatic free energy of a given system is then obtained by integrating over the charge density and electrostatic 
potential values over all points. The electrostatic component of the free energy of ligand and protein binding can then 
be determined according to the following cycle, including the energy of transfer of each solute (protein, ligand, complex) 
 ( ) ( ) 4 ( )r r r    
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from vacuum (or a low dielectric reference environment) to a high dielectric solvent, and the electrostatic energy of 
protein-ligand binding (ECoulomb in a medium with fixed ) calculated according to the Coulomb equation. 
Figure 9. Thermodynamic cycle for determination of electrostatic contribution to binding free energy  
including solvation (Gelectr) 
 
Model building by multivariate linear regression 
The values of user-selected 
iX  terms (such as Gelectr described above) of the protein-ligand complexes in combination 
with estimates of 
bindingG  from experimental measures form a set of equation as below allowing the fitting of the 
unknown coefficients (ci).  
Building such a model presupposes two things: that the terms (
iX ) employed to build the model are consistently 
evaluated relative to a correct representative of each protein-ligand complex, and that the error in the corresponding 
experimental values used to calibrate the weighting terms is low enough to capture a trend. The training set 
bindingG  
values should ideally be uniformly distributed over the range of interest; the resultant model is used for interpolation, 
and not extrapolation. 
The values of 
bindingG  used to build the model in this thesis were calculated from literature-reported iK and 50IC
values, the latter being more experimental condition-dependant (substrate concentration, pH, temperature) than the 
former (pH, temperature) but more often reported. In spite of their relative independence to experimental conditions, 
even 
iK values suffer from variation (due to systematic errors between data sources and precision errors). Kalliokoski 
has estimated the expected error in 
iK  values of a given inhibitor-protein pair reported by different labs in the ChEMBL 
database [39].  
50IC variability between measurements has been reported by the same author [12]. 
Any inaccuracy in the 
bindingG  values used to build the model limits the maximum correlation attainable. Given this, it 
is worthwhile to further evaluate the model before use. Since the number of complexes having a reported 
iK or 50IC
1 1 2 2 ...binding i iG c X c X c X   
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value and a known or highly probably binding mode in the target is limited, there is an interest to use all data in the 
model “training set”. No test set then remains to evaluate the models predictive performance. In such a case, a cross-
validation correlation coefficient may be helpful; it is generated by leaving one data point out (“leave-on-out”) and 
comparing the experimental to predicted (according to a model generated by the remaining data points) free energies 
of the excluded point. As per Golbraikh, the cross-validation correlation coefficient is useful to eliminate poor models, 
but the standard cut-off of 2q  > 0.6 is insufficient to validate a good one [40]. 
Another approach to evaluate a model is to compare its correlation and cross-validation correlation coefficients with 
those of a large number of models generated by datasets in which each set of 
iX  values is associated with a randomly-
generated value of 
bindingG . If the proposed model is superior in both coefficients to those on random bindingG  
assignment, the model outperforms a random selection.  
Nonetheless, even having passed various tests to eliminate clearly poor performing models, the remaining model may 
suffer inaccuracies and accordingly the output values (“scores”) should not be considered as absolute measures of 
binding affinities but rather as coarse indicators of a range in which binding affinity is likely to lie. It is then reasonable 
to define a “score” cut-off above which true high affinity binders (“true positives”) are likely to significantly outnumber 
false positives. To this end, a receiver operator characteristic (ROC) plot may be helpful in selecting this cut-off value.  
 Figure 10. Representative ROC plot from [41] 
If a sufficient number of ligands remain above the cut-off, a diverse set of these can be selected for experimental 
evaluation.  
 
1.2.3 DIGITAL LIBRARIES 
Once a docking algorithm and a target-calibrated scoring function are defined, the combination may be applied 
prospectively to identify putative high affinity binders of the target protein. This presupposes that such high affinity 
binders are in the library to be screened. For this reason, large libraries are of interest.  
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On the other hand, it is more efficient to tailor a library in advance of docking if desirable characteristics of the potential 
inhibitors are known (the presence of hydrogen bond donors or acceptors in view of the target binding site and further 
drug-like properties). Ligands containing privileged chemical moieties known to bind sub-pockets of the target binding 
site may help to ensure correct binding of that motif, while the remainder of that ligand explores new pockets.  
In the fragment-based docking approach known as “ALTA”, small fragments (MW < 300 g/mol) with limited torsional 
degrees of freedom are first docked to the target binding site and ranked according to metrics of binding affinity. High 
ranking fragments then serve to perform a substructure search on a large digital compound library, resulting in a 
collection of ligands containing these select moieties. These ligands are then docked to the binding site, with 
conformational filtering to ensure their respective selected fragments are positioned as previously identified, prior to 
scoring the ligand pose. The ALTA approach may be of particular interest when the project objectives include the 
identification of a ligand binding strongly to a new sub-pocket of the binding site, as was a goal in this thesis.  
Figure 11. Fragment-based ALTA procedure as implemented in the present thesis with use of DAIM [42], SEED [43,44], RDKIT 
[45], VINA [46] and LIECE-type evaluation of binding affinity [35] 
A last approach to library definition is mentioned here: as discussed previously, compounds having demonstrated low 
toxicity are of great interest to repurpose [47] because they have already overcome a major hurdle in development that 
is difficult to predict in advance. This motivated the docking (as of “VINA ligand docking step” in Fig. 11) of a collection of 
post-clinical trials phase I compounds in a project of this thesis.  
 
1.2.4 HOMOLOGY MODELLING 
Homology modelling was used in this thesis to: 
- Build a homology model of human macrodomain-containing protein 2 (MacroD2) for which no crystal or NMR 
structure was available. 
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Proteins are chains defined by their particular sequence of covalently-bonded amino acid residues, of which 21 naturally 
occur in humans. Whereas protein amino acid sequences are widely available, their corresponding three-dimensional 
structures are less so.  One option, then, if a structure of a protein of known sequence is required, is to build a 
comparative homology model of this structure. This requires that its sequence be homologous to another protein for 
which a structure is available. Accordingly, a first step is to perform a sequence alignment of the protein to be modelled 
over a large database of known sequences in order to find potential templates. Given the need for speed in view of the 
breadth of potential alignments, alignment algorithms are heuristic; the BLAST (Basic Local Alignment Search Tool) 
algorithm [48] preliminarily identifies short matching regions before aligning neighboring segments and evaluating the 
result. The selection of aligned protein to use as template for a homology model can be guided by the degree of 
sequence identity, from which expected structural differences have been quantified [49-52].  
The target-template sequence alignment and template structure are then used to generate a three-dimensional model 
of the target structure. MODELLER [53,54] implements comparative modeling by “satisfaction of spatial restraints” 
derived from the sequence alignment and resulting in a set of probability distribution functions (pdfs) to constrain main 
and side-chain conformations. These pdfs are step-wise added to a single objective function relative to which the 
corresponding subset (and ultimately complete set) of modeled atomic coordinates are minimised. The lower the final 
objective function value, the better the fit of a given model to the applied restraints.  
 
1.2.5  MOLECULAR DYNAMICS 
Molecular dynamics was used in this thesis relative to: 
- determine physico-chemical differences between the binding sites of two related proteins, human ARTD-1 and 
ARTD-2, taking into account the intrinsic flexibility of these enzymes as observed by molecular dynamics 
simulations; 
- identify protein conformations falling within densely explored regions of phase space (“energetically-favourable” 
basins of kinetically-clustered conformations) of ARTD-1 that are distinct from crystal structures and present 
physico-chemical differences relative to ARTD-2 for use in a high-throughput in silico docking campaign; 
- evaluate the stability of a homology model of human MacroD2; 
- identify residues in MacroD2 putatively forming interactions with analogues of a newly-identified endogenous 
ligand; 
- detect stable water molecules in the MacroD2 binding site as observed in molecular dynamics trajectories of the 
explicitly solvated protein-ligand complex. 
Biological systems are systems in motion. Evidence of this issues from experiments on small and large constituents of 
cellular systems: from IR-observed bond vibrations, to protein crystallographic B-factors, to atomic fluctuations derived 
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from NMR relaxation rates and structural ensembles, to temporal evolution of distance from FRET measurements [55-
58]. To the extent that experimental techniques, though quantifying a metric of temporal motion within a system, are 
limited in resolution, either by measuring values at a level of abstraction from constituent atoms or by providing only a 
series of static representatives of a system, molecular dynamics provides a means to evolve classical degrees of freedom 
of atoms in a system over time. As per [59], one use of molecular dynamics is to “obtain a description of the system at 
equilibrium, including structural and motional properties”. 
If we consider a collection of single atoms in a system and hypothesize that their individual movements can be 
approximated by classical laws of physics, Newton’s equation applies to trace their motion over time, in accord with the 
forces applied to the constituents of the system.  
These forces can act to limit the available values of each degree of freedom of the system. An atom of a protein in a 
biological system at body temperature is covalently bonded to at least one other; a potential energy field (“forcefield”) 
can be defined from which this force as a function of bond length is obtained from its negative gradient.  
Ideally, this field should be represented by continuous function that recapitulates experimental observables. The Morse 
potential is an example of an empirical forcefield model of bond potential, appropriately including a distance limit above 
which potential energy becomes distance-invariant and atoms are no longer bonded; when atoms approach so as to 
overlap their orbitals, potential energy rapidly rises, translating in the expected strong force to return the inter-atom 
distance to that at a potential energy minimum.  
Figure 12. Morse and harmonic potentials 
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Given that a protein counts large numbers of bonded atom pairs, it is desirable to use a simple forcefield with few terms; 
in the interest of simulating biologically-relevant time scales, this is in fact essential. At human body temperature, 
covalent bonds do not break unassisted and the potential energy can be simplified to a harmonic potential. 
The above bond potential energy model appears with further terms in the widely exploited empirical CHARMM22 
forcefield [60] for biomolecules as a function of system coordinates given below: 
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The reader is directed to [60] for a more complete discussion of the terms. The first five summations are relative bonded 
interactions (within three covalent bonds), and scale with ( )O N . The evaluation of non-bonded terms, by contrast, are 
based on pairwise potentials that scale with 2( )O N , accounting for a large part of calculation time. For this reason, 
distance cut-offs are applied to limit non-bonded term evaluation. The use of a cut-off can be problematic for two 
reasons: (a) it implies a discontinuity at the cut-off, and (b) important long-range electrostatic interactions are ignored. 
The first issue can be circumvented by adding a smoothing potential over a short range at the cut-off (“SWITCH”) or by 
shifting the potential (“SHIFT”). The second is addressed in view of the use of system replicates in all directions 
surrounding the simulated system in order to approximate electrostatic interactions beyond the simulation box; these 
replicates provide charges appearing periodically over space. This periodicity is suitable to description in Fourier space. 
Ewald summation (and the faster PME method) accordingly divide short-range and long-range components of 
electrostatic potential. 
Charge interactions are determined by the Coulomb equation relative to fixed point charges centered on the atom 
nuclei whose magnitude and sign are either provided in the forcefield parameters or determined by distribution of 
formal charge as a function of relative electronegativity and the hybridisation state of the atoms; the fixed point charge 
representation ignores polarisation effects that might redistribute charge as a function of the environment defined 
beyond directly bonded partners and the generation of  asymmetry dipoles (when the centroid of electronic and nuclear 
charge do not overlap).  
Forcefields are continuously evaluated relative to experiment, offering opportunities for their improvement. In view of 
observations of overstabilised secondary structures attributed to forcefield bias, the CHARMM22 forcefield has since 
been extended by additional terms to improve treatment of backbone dihedrals (now CHARMM27 ) [61]. 
Given a defined analytical form of the forcefield, it is necessary to provide the parameters of their function. These can 
be determined ab initio by quantum mechanical calculations and/or fit to reproduce empirical data. It is important that 
2
0( )BE K r r 
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parameters be derived in view of a given analytical forcefield form and appropriate to the system they are modeling. 
The CHARMM22/27 forcefield has associated parameters for all atoms (i.e. including explicit hydrogens) of proteins, 
lipid, nucleic acids and, importantly, water molecules and ions; these parameters are “consistently” derived, meaning 
that they can be used in combination with one another. Indeed, molecular dynamics simulations are often run in a “box” 
containing the biomolecule of interest immersed in explicit solvent (water molecules and salt ions providing 
physiological salt concentrations and system charge neutrality). Accordingly, the objective in setting the parameters of 
the non-bonded terms must “result in balanced protein-protein, protein-water and water-water interactions” [60]. The 
applicability of the CHARMM22 forcefield has recently been improved by the determination of parameters suitable for 
small-molecules [62]. Whereas prior-mentioned parameters may be accurately defined and assigned their limited 
breadth of atom types and environments, small-molecule are diverse and assignment of their parameters is often by 
analogy to a limited set of fully parameterised fragments [63]. 
The above discussion was undertaken to underline that potential energy forcefields may include terms that accord with 
physical models, but which remain approximate. Indeed, “the errors introduced by the use of empirical potentials are 
difficult to quantify” [59]. Nonetheless, armed with a forcefield, the equations of force above provide the basis to evolve 
atomic coordinates over time. 
The potential energy function is derived with respect to (Cartesian coordinate-derived internal) coordinates, and 
evolved by its integration with respect to time. Time-reversible numerical integrators such as provided by the verlet 
algorithm approximate the positions, velocities and accelerations at t t  by a truncated Taylor series. While affected 
by precision limitations, what is critical is that such integrators avoid generating large instabilities and systematic drifts. 
The selection of the time step requires that it be smaller than the highest-frequency motion in the system. For this 
reason, high-vibrational frequency covalent bonds including hydrogen are often constrained to allow a larger time step 
to be used. 
Molecular dynamics result in a trajectory (series of states) contained within phase space, where phase space consists of 
the set of all accessible states of a system subject to the thermodynamic constraints. The above-described system and 
related equations describe the evolution of the simulated system at constant total energy, which does not reflect the 
thermodynamic properties governing the ensemble of protein conformations in its cellular environment. We can 
accordingly change ensembles in which to evolve our protein by coupling the system to a heat bath and a barostat, thus 
moving to the statistical mechanical isothermal-isobaric NPT ensemble (where N refers to the fixed number of atoms of 
a closed system, which is ensured during simulation by the use of periodic boundary conditions which circulate atoms 
exiting a boundary the system directly to enter on the opposite boundary side). This can be achieved by reformulation 
of the equation of motion and its integrator to a set of equations including, at each time step, random stochastic forces 
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(corresponding to collisions with fictive particles of the heat bath), friction and a degree of freedom corresponding to 
the volume of the simulation system. 
With correct sampling in the NPT ensemble, the distribution of density of visited states over phase space will reflect, at 
equilibrium (achieved by exhaustive sampling), the relative free energies of different phase space regions: energetically 
favourable states are visited more often than less favorable states. Barrier regions are visited even less, though the 
thermostat-governed velocities will allow their occasional occupation from which different basins are reached. The 
density of state visitation can be clustered into (strongly connected) macrostates within a network, and a two-
dimensional slice (“projection”) identified to visualize the free energy evolution between states ordered according to a 
given progress index. In the present thesis, a cut–base free energy profile was used to visualize and identify free energy 
basins, from which states were selected for a docking campaign [64]. This approach estimates the partition function (Ξ 
in the NPT ensemble) of a basin based on its number of visitations during the trajectory; the ensemble of states 
representing different transition paths between two given basins can be evaluated by the Ford-Fulkerson theorem to 
determine the flow rate between them [65].   
 
1.3 AIMS AND STRUCTURE OF THIS THESIS 
 
The main aim of the present thesis was to identify potent and selective inhibitors of epigenetic targets. Several 
computational methods were specifically used to: 
- Determine physico-chemical differences between the binding sites of two related proteins, human ARTD-1 and ARTD-
2, taking into account the intrinsic flexibility of these enzymes as observed by molecular dynamics simulations (Chapter 
2); 
- Based on molecular dynamics simulations, identify protein conformations falling within densely explored regions of 
phase space (“energetically-favourable” basins of kinetically clustered conformations) of ARTD-1 for use in a high-
throughput in silico docking campaign (Chapter 2); 
- Define a scoring function to apply to small-molecule poses within the ARTD-1 binding site with the aim of enriching the 
fraction of high binding affinity compounds of a library above a selected score cut-off (Chapter 2);  
- Propose for experimental validation small molecules binding ARTD-1 with putative high affinity and forming selective 
interactions with the ARTD-1 binding site not available to be formed with ARTD-2 (Chapter 2); 
- Propose for experimental validation small-molecule compounds binding ARTD-1 with putative high affinity based on a 
library of select post-clinical trials phase I compounds and FDA approved drugs (Chapter 3); 
- Generate a homology model of human macrodomain-containing protein 2 (MacroD2) (Chapter 4); 
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- Identify residues in MacroD2 putatively forming interactions with analogues of a newly-identified endogenous ligand 
and to detect stable water molecules in the MacroD2 binding site as observed in molecular dynamics trajectories of the 
explicitly solvated protein-ligand complex (Chapter 4). 
Further, studies in mice were used to determine pharmacokinetic parameters and to establish tumor growth inhibition 
efficacy of small-molecule inhibitors of multiple tyrosine kinases identified in silico (Chapter 5). 
In a side project, a novel web-based platform was developed to render more user-friendly the suite of programs for 
fragment-based docking developed in the Caflisch group since 1999 (Appendix A). 
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2. IN SILICO IDENTIFICATION OF ARTD-1 SELECTIVE INHIBITORS 
 
2.1  INTRODUCTION 
 
2.1.1  ARTD FAMILY OF PROTEINS 
Poly(ADP-ribose) polymerase (PARP) family members PARP-1 and PARP-2 are nuclear proteins belonging to the ADP-
ribosyl transferase family of enzymes. Using nicotinamide adenine dinucleotide (NAD+) as substrate, they synthesize 
nicotinamide along with a negatively-charged ADP-ribose homopolymer (containing up to 200 ADP-ribose units and 
generally branched), formed in covalent attachment to one or more nuclear receptor proteins [1-4]. 
Figure 13. ARTD-1 binding interactions with NAD+ donor and acceptor substrates adapted from [5] 
Acceptor in cyan, donor nicotinamide in pink, donor phosphate in blue, donor adenine in purple 
PARP-1 (116 kDa) was the first PARP family member to be identified in a 1963 publication referring to its activity [6], and 
was generally referred to as simply PARP up until the identification of further family members, including PARP-2 (62 kDa) 
in 1999 [7]. Today, 17 PARP proteins are known [8]. PARPs 1 and 2 synthesize poly(ADP-ribose) in response to DNA strand 
breaks [9,10] and thus participate in a signaling mechanism of a eukaryotic cell's recovery process. They have since been 
renamed ARTD-1 and ARTD-2 (ADP-ribosyltransferase diphtheria toxin-like) following their grouping into a larger family 
of structurally similar enzymes with catalytic functions leading to addition of a monomer or polymer of ADP-ribose to the 
recipient protein [11]. This new nomenclature will be applied hereon in.  
ARTD-1 comprises three domains [12,13]. The N-terminal domain includes zinc fingers binding DNA at sites of strand 
breaks [14-17]. This is neighbor to the “automodification” domain (AD), which can be the acceptor of another ARTD 
protein’s ADP-ribose polymer. Finally, a highly conserved catalytic domain having a characteristic β-α-loop-β-α motif that 
includes the binding site of the donor NAD+ forms the C-terminus [18,19].  
Y907
K903
L985
M890
G876
S904
G863
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Figure 14. ARTD-1 domains from [17] 
Following DNA binding, a rapid up-to 100-fold activation takes place resulting in poly(ADP-ribosyl)ation of receptor 
proteins, most of which are themselves ARTD proteins, but also include histones and polymerases. Automodification 
results in inactivation of the ARTD recipient. Addition of the poly(ADP-ribosyl) polymer to receptor proteins triggers 
chromatin structure relaxation and results in recruitment of the base excision repair (BER) proteins, including XRCC1 and 
DNA ligase III. Overactivation of ARTD-1, however, may result in cellular depletion of NAD+ leading to necrosis [20]. Hence, 
ARTD-1 has two seemingly contradictory roles as a function of DNA damage extent: assisting in the recruitment of DNA 
repair proteins or inducing cell death by necrosis.  
The above suggests two motivations to inhibit ARTD-1 enzymatic activity. The first is to limit necrosis-inducing 
overactivation of ARTD-1 in otherwise healthy cells during blood reperfusion following ischemia (i.e. subsequent to a 
stroke or heart attack), an approach that has been validated in mice models [21]. The second is to inhibit the DNA-repair 
function of ARTD-1 in diseased cells in order to support programmed cell death. Indeed, it is interesting to consider the 
role of ARTD-1 in cancer cells under two conditions. In general, alkylating chemotherapeutics and radiation induce the 
formation of DNA strand breaks [22]. If sufficient breaks accumulate in a diseased cell, desired cell death results. However, 
the effects of chemo- and radiation therapy are partially countered by ARTD's DNA repair activity. Inhibiting ARTD-1 in 
combination with chemo- and radiation therapy has been reported with some success, and knock-out mice deficient in 
either ARTD-1 or ARTD-2 are hypersensitive to alkylating agents and gamma-irradiation, both of which induce single-
strand breaks [23].  
The second condition considered desirable to target with ARTD-1 inhibitors are those involving cancer cells having 
defective DNA double strand break repair mechanisms. In presence of ARTD-1 inhibitors, DNA single strand breaks fail to 
be repaired and, during replication, become double strand breaks repaired by ARTD-independent mechanisms. BRCA-1 
and BRCA-2 deficient tumor cells lack a functional double strand break repair pathway, such that ARTD-1 inhibitors have 
potential as single agent therapeutics. Healthy organisms treated with ARTD-1 inhibitors remain viable and ARTD-1 
deficient mice were found to be free of abnormal rates of spontaneous tumor development [24]. 
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2.1.2  ARTD-1 AND -2: SIMILAR PROTEINS, DIFFERING ROLES? 
An estimated near 90% of nuclear ARTD activity is accounted for by ARTD-1 and the remaining 10% by ARTD-2. ARTD-2 
shares many of the same receptor proteins as ARTD-1. However, different DNA structures may be recognised; indeed, 
this is unsurprising given that ARTD-2 lacks the traditional DNA binding domains of ARTD-1 (Fig. 16). 
According to Schreiber [25], ARTD-2 binds DNA single strand breaks less efficiently than does ARTD-1, instead recognising 
gaps and flap structures. Though both ARTD-1 and ARTD-2 deficient phenotypes are hypersensitive to ionising radiation 
and alkylating agents, ARTD-2 deficient phenotypes appear less sensitive to low-dose radiation. In ARTD-1 deficient 
phenotypes, XRCC1 is recruited to DNA single strand breaks, whereas this recruitment is absent in ARTD-2 deficient 
phenotypes. Defects in spermatogenesis, adipogenesis and T cell development are seen in ARTD-2 but not ARTD-1 
knockout mice, suggesting tissue-specific requirements for ARTD-2 [26,27]. ARTD-2, but not ARTD-1, is an important 
mediator of T-cell survival during thymopoiesis by preventing the activation of DNA-damage-dependant apoptotic 
responses [28]. Moreover, as discussed by Pellicciari, “the cell executioner role” cannot be taken over by ARTD-2 in ARTD-
1 deficient animals [29]. The differing roles of ARTD-1 and ARTD-2 continue to be elucidated. That these two ARTDs may 
act at distinct steps and/or with distinct partners and/or in distinct subcellular localisations defines a motivation to 
develop inhibitors that are highly specific to each of these isoforms.  
 
2.1.3  OVERVIEW OF KNOWN ARTD-1 AND ARTD-2 INHIBITORS 
To date, most ARTD inhibitors mimic of the nicotinamide moiety, forming hydrogen bonds with Ser904/457 (ARTD-
1/ARTD-2) and Gly863/429, and -stacking interactions with Tyr907/473. Given that the mode of NAD+ binding is highly 
similar in ARTD-1 and ARTD-2, inhibitors relying essentially on interactions with the nicotinamide binding site are not 
selective.  
The few inhibitors reported to be selective are presented in Fig. 15. Of these, only one is accompanied by a co-crystal 
structure allowing confirmation of the nature of protein-ligand interactions including those that provide selectivity. 
Nonetheless, all structures suggest selective interactions outside of the nicotinamide binding site as discussed hereafter. 
 
2.1.4  PROJECT OBJECTIVES 
The objective of this work was to identify fragments and ligands binding to ARTD-1 with high potency (characterised by 
an IC50 or Ki of ≤ 10 µM) and forming interactions therewith not available in ARTD-2, such that these inhibitors are 
selective for ARTD-1. Selectivity is defined as a potency on ARTD-1 that is at least 10 fold greater than on ARTD-2. Such 
inhibitors have potential for use as tool compounds and possibly as therapeutic inhibitors. This work further more 
generally addresses the question of whether in silico methods can be used to identify new modes of selective interactions 
within a target binding site. 
 
ARTD-1 selective inhibitors 
 32 
 
Figure 15. ARTD-1 and ARTD-2 selective inhibitors, with example of binding modes for compound a) having co-crystal structure 
with ARTD-1: ARTD-1 selective inhibitors a)[30] and b)[31], ARTD-2 selective inhibitors c) [32] and d) [33]. Nicotinamide binding 
moieties are in pink.  
 
2.2  ARTD-1/-2 BINDING SITE COMPARISON 
 
 
2.2.1  SEQUENCE COMPARISON AND STRUCTURAL ALIGNMENT 
ARTD-1 and -2 catalytic domains exhibit high (64%) similarity. The catalytic pocket may be divided into sub-sites (Fig. 13). 
The acceptor site is occupied by the terminal ADP moiety of the poly(ADP-ribose) chain. The donor site is occupied by 
NAD+, and may be further subdivided according to nicotinamide (NI), phosphate (PH) and adenine (AD) binding residues 
(Fig 17). 
 
c) UPF-1069
ARTD-1 IC50: 8 µM
ARTD-2 IC50: 0.3 µM
A880
I879
P881
G863
S904
d) Ishida
ARTD-1 IC50: 101 nM
ARTD-2 IC50: 8 nM
L769
D766
Y907
a) FR257517
ARTD-1 IC50: 13 nM
ARTD-2 IC50: 500 nM
b) BYK204165
ARTD-1 IC50: 45 nM
ARTD-2 IC50: 4 µM
Figure 16. Human ARTD-1 and ARTD-2 sequence alignment performed on UniProt [90] 
with matching residues in the vicinity of the catalytic binding pocket marked by “*” and 
NAD+-binding residues of ARTD-1 in red
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To determine positional equivalence of binding site residues, human ARTD-1 and ARTD-2 crystal structures 3GJW and 
3KJD, respectively, were overlaid using WITNOTP [34] giving an RMSD of 0.995 Å. Fig. 17 depicts residues involved in 
binding NAD+ and the acceptor substrate. These residues are largely conserved, and account for a significant portion of 
the binding site. Correspondence between further residues along the binding sites of ARTD-1 and ARTD-2 was additionally 
determined, over a total of 46 residues per site. 
 
2.2.2  RESIDUE ACCESSIBILITY TO BINDING SITE: A MOLECULAR DYNAMICS INVESTIGATION 
Residues equivalently located within the ARTD-1 and ARTD-2 binding sites as determined by the above structural 
alignment were investigated by molecular dynamics for their accessibility to intramolecular binding as measured by their 
solvent accessible surface area (SASA).  
Donor nicotinamide
(NI) binding site
Donor adenine (AD) 
binding site
Donor phosphate
(PH) binding site
Substrate 
binding site
M890/456
L985/N555
K903/241
H862/428
R878/444
D770/339
G864/442
D766/E336
E763/Q332
E988/558
Y907/473
S904/470
G863/429
Y896/462
Figure 17. Human ARTD-1 and ARTD-2
overlap and depiction of subsite
residues involved in binding donor NAD+
and substrate
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Briefly, water molecules, ions and ligand were removed from PDB structures 3GJW (ARTD-1, resolution 2.30 Å) and 3KJD 
(ARTD-2, resolution 1.95 Å), and each was protonated such that aspartate and glutamate side-chains were negatively 
charged, arginine and lysine side-chains positively charged, while histidines were maintained neutral. Missing ARTD-2 
loop residues (Thr349 to Gln352) of 3KJD were generated using the backbone coordinates of the equivalent loop of 
overlaid ARTD-1; side-chain atom coordinates were built using the autopsf function of VMD [35] and loop atoms 
minimised with CHARMM [36]. The obtained proteins were each immersed in a rectangular box of pre-equilibrated 
(TIP3P) water molecules having a minimal distance of 12 Å between the boundary and any protein atom. Sodium and 
chloride ions were added to neutralize the systems and to reach an ion concentration of 150 mM. Parameters for the 
system were from the CHARMM27 forcefield. Following minimisation, 0.5 ns of NVT and subsequent 0.5 ns of NPT 
equilibration during which the protein heavy atoms and protein Cα atoms were, respectively, positionally-restrained, 
molecular dynamics trajectories totalling 50 and 100 ns for ARTD-2 and ARTD-1, respectively, were collected in the NPT 
ensemble with a 2 fs time step at constant temperature (310 K, using the Langevin thermostat with a coupling coefficient 
of 1 ps-1 applied to heavy atoms) and constant pressure (using the modified Nosé-Hoover method with Langevin dynamics 
to control barostat fluctuations, with target pressure: 1.01325 bar; piston period: 200 fs; damping time scale: 100 fs) as 
implemented in NAMD [37-39]. The van der Waals and short-range electrostatic interactions were determine up to a cut-
off of 10 Å. Periodic boundary conditions were applied to avoid finite size effects, and long-range interactions were 
evaluated by particle-mesh Ewald (PME) summation.  
Figure 18. RMSD evolution over trajectories of ARTD-2: each panel represents a trajectory commenced from the same starting 
structure but with different seeds for the initial distribution of velocities. 
Temporal protein conformation stability relative to the starting structure was evaluated based on the RMSD evolution of 
all Cα atoms as calculated with WORDOM [40], (Fig. 18). To determine the solvent accessible surface area (Fig. 19) of 
each residue side-chain along the binding sites of ARTD-1 and ARTD-2, the WORDOM [41] molecular surface (“ASURF”) 
calculation was run relative to side-chains atoms as of Cβ using the Gepol numerical algorithm [42] with van der Waals 
radii from Rose [43] . The radius of the solvent sphere used to trace the surface was 1.4 Å and “NDIV” was set to 5. 
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Figure 19. Solvent Accessible Surface Area from [42], wherein spheres indicated with “S” model the solvent and remaining spheres 
represent protein atoms; the thick line corresponds to the SASA (also referred to as ASURF) 
Of the 46 investigated residues per binding site, those presenting physico-chemically different side-chains at equivalent 
positions in ARTD-1 and ARTD-2 where at least one of these side-chains is solvent accessible, as well as conserved residues 
with marked differences in solvent accessibility, were examined for their potential to interact with a ligand to form 
selective interactions. A set of these are shown in Fig. 21. 
Interactions with Asp766/Glu355 have previously been exploited in the search for selective ligands [33,44]. Given the 
proximity of Asn767 to the nicotinamide binding site and the significant difference in possible interactions relative to its 
alanine counterpart in ARTD-2, this residue was selected for investigation of potential to form ARTD-1 selective hydrogen 
bonds with a ligand. It is of note that although ARTD-1 Asn767 is mentioned as an interaction partner of the quinazoline 
ligand of PDB 1UK0 [30,45], both structures of the unit cell of this PDB suggest that any such interaction is not direct, 
though possibly water-mediated.  
Figure 20. Backbone Cα overlaid structures of PDB 1UK0 unit cell with ligand and Asn767 in stick representation, and crystal water 
oxygens near to Asn767 in spherical representation; dashed lines show the measure of indicated distance in Å 
 
 
ARTD-1 selective inhibitors 
 36 
  
Figure 21. MD-based SASA distribution of residues providing potential basis for selective interactions with
ARTD-1 (green)  and ARTD-2 (magenta); the nicotinamide binding site is presented as a pink surface
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2.3  ARTD-1 PROTEIN CONFORMATIONS FOR DOCKING 
 
2.3.1  CUT-BASED FREE ENERGY PROFILE 
 
Following selection of Asn767 as target residue of the ARTD-1 binding site, the ARTD-1 MD trajectory was further analysed 
to identify alternative, energetically-favourable binding site conformations in which Asn767 remains accessible, as 
evaluated based on its side-chain SASA. For this, a one-dimensional cut-based free energy profile (cFEP) with a normalised 
partition function as progress coordinate was prepared [46]. The input for the cFEP calculation is a network of nodes 
containing trajectory frames, joined by edges whose weights are proportional to the transitions between them. Trajectory 
frames were first clustered (“binned”) based on RMSD using the leader algorithm in WORDOM relative to all non-
symmetric heavy atoms of the binding site lying within 7 Å of Asn767. Node partitioning into two groups according to the 
minimum-cut procedure gives the partition function of the cutting surface separating them, from which the free energy 
barrier is derived. By iterative determination of the minimum cuts between all pairs of nodes, all barriers and basins are 
isolated. The RMSD cut-off value of 0.85 Å as per Fig. 22 was selected to ensure consistency with a diffusive regime as 
per [47]; use of this cut-off meets the requirement that F be shifted by 0.35(ln(√2)) consequent to the use of every second 
frame of the trajectory (a doubling of dt). 
 
Figure 22. cut-based Free Energy Profile (cFEP) and diffusivity evaluation with different clustering cut-off (“cut”) values 
 
 
2.3.2  BINDING SITE RESIDUE DIHEDRAL ANGLES AND SASA WITHIN BASINS 
Firstly, the SASA of the Asn767 side chain was determined over the cFEP in order to define basins in which its values were 
desirably high. Secondly, the dihedral angle values of side chains along the binding site were mapped along the cFEP and 
frames were selected to fall within populated values of each of these dihedrals with the respective free energy basins. A 
selection of main results from this analysis is given in Fig. 23. 
 
 

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2.3.3 SUMMARY OF SELECTED PROTEIN CONFORMATIONS 
Only three PDB structures of human ARTD-1 include Asn767 conformations providing non-zero side-chain atom SASA 
(PDB ID: 1UK0, 1UK1, 2RCW). The location of the closest MD-generated protein conformation (RMSD<1 Å) to each PDB 
conformation along the cFEP places all three in the third basin.  
II
a) b)
c)
I
I
e)
d)
f)
III
Arg878
Leu769
Tyr689
Asn767
Figure 23. SASA and dihedral angles of
selected residues over basins and barriers
Panel c) shows the
histogram of Leu769 χ2
dihedral angles in cFEP
basin II; Panel f) shows the
histogram of Asn 767 side-
chain ND2 SASA in cFEP
basin I
III
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Accordingly, PDB structures 1UK0 and 2RCW were retained as representatives of basin III. Two additional MD-generated 
protein conformations were selected for docking, one from each of cFEP basins I and II with high Asn767 side-chain SASA 
and dihedral angles consistent with highly populated values in their respective basin.  
Figure 24. Selected protein conformations for docking: MD-generated frames were selected to represent basins I (pink) and II 
(yellow), while 2 PDB structures represent basin III (1UK0: green, 2RCW: blue) 
 
 
2.4  ARTD-1 SCORING FUNCTION 
 
2.4.1  TRAINING SET LIGANDS AND POSE GENERATION 
 
A set of 32 inhibitors of ARTD-1 with reported Ki or IC50 values (ranging from 3 nM to 190 µM) and comprising a known 
nicotinamide binding moiety were used to build a scoring function to rank ligands in a high-throughput virtual screening 
campaign; this moiety requirement facilitated recognition of the probable binding mode.  
Ligand poses were established in a single conformation of ARTD-1, namely that of PDB structure 1UK0. Use of a single 
structure removes variation in the subsequently-calculated electrostatic term due to differences in protein conformation 
outside of the binding site. The PDB 1UK0 protein structure was prepared by removing all water molecules, ions and 
ligand and subsequently protonating such that aspartate and glutamate side-chains were negatively charged, arginine 
and lysine side-chains positively charged, while histidines were maintained neutral. Hydrogen atom coordinates were 
minimised with CHARMM.  
E703
N767
Y889
R878
D766
Y907
H862
S904
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For ligands having a co-crystal structure with ARTD-1, poses were generated by backbone Cα atom overlay of the co-
crystal protein with those of PDB structure 1UK0 using WITNOTP [34]. Remaining ligands were docked to the binding site 
of the protein conformation of PDB 1UK0 using VINA [48], and visually inspected for recapitulation of the expected 
binding mode at the nicotinamide binding pocket.  
 
Figure 25. Binding modes of 32 ARTD-1 inhibitors used to develop a scoring function in the ARTD-1 binding site of PDB 1UK0 
Hydrogen bonds to NI binding site are shown as dashed lines 
 
 
2.4.2 EVALUATION OF TERMS 
Protein atoms were parametrised with CHARMM27 parameters while the ligand was parametrised according to the 
CHARMM General Force Field [49] with MATCH [50]. Docked poses were minimised with CHARMM (by the iterative 
steepest descent method for 500 steps followed by the conjugate gradient method for 10’000 steps), allowing residues 
with atoms within 5 Å of the ligand to remain flexible along with the ligand during minimisation. 
A model for binding affinity was then built by multivariate linear least squares regression to determine the coefficients 
based on a set of equations of the form: 
 
The number of rotatable bonds (Nrot) was calculated by DAIM [51]. Change in SASA on binding (SASA) was calculated 
using CHARMM [36] as the difference in SASA of the complex to the SASA of the free protein and ligand (SASA = 
SASAcomplex – SASAprotein - SASAligand) using the “COOR SURF” command with a solvent diameter of 1.4 Å and atom radii 
from the CHARMM27 parameter file for the protein and CHARMM36 CGenFF parameter file for the ligand. The 
intermolecular van der Waals energy (EvdW) was calculated with CHARMM applying a switching function between 10 Å 
and the truncation distance of 12 Å. Electrostatic energy (Gelectr) was calculated according to the thermodynamic cycle 
of Fig. 9 with CHARMM, where Gelectr  is a sum of two terms (ECoulomb + Gsolv): the Coulombic energy (ECoulomb, 
calculated with fixed =2 and infinite evaluation cut-off) was evaluated relative to all atom pairs separated by at least 3 
50,exp 1 2 3 4 5ln(IC )binding rot binding vdW electrG RT cN c SASA c E c G c         
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covalent bonds, and the free energy of desolvation on complex formation, calculated with the CHARMM PBEQ module 
and a focussing procedure with a final grid spacing of 0.3 Å. These latter two terms (EvdW, Gelectr) correspond to and 
were calculated consistently with those of the two-parameter model with rigorous treatment of continuum electrostatics 
(i.e. numerical solution of the Poisson equation by the finite difference method) reported by Huang [52]. 
 
 
2.4.3 SCORING FUNCTION: CORRELATION AND CROSS-VALIDATION CORRELATION 
Multivariate linear least squares regression was performed including cross-validation by the leave-one-out procedure, 
applied in turn to (i.e. leaving out in turn) each of the input data sets. Models for all subsets of the set of Xi’s were 
determined, with coefficients obtained for each model. The 3-parameter model given in c) of Fig. 26 had a cross-validation 
correlation coefficient (q2) of 0.61. 
 
Figure 26. Scoring function model c) and evaluation relative to a) 100’000 and b) 1 million models build with random values of G 
within the G range of the original set: the model of c) is represented by a red dot in panels a) and b) whereas  
random models are shown as blue dots 
 
The model of Fig. 26c) was evaluated relative to sets of models (a) 100’000 and b) 1 million in Fig. 26) issued from datasets 
in which Xi values were maintained and G values randomly assigned over the range of G values of the original set. That 
the scoring function model remains largely superior with few exceptions even relative to 1 million such random models 
attests to its expected predictive power. 
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2.4.4 SCORE CUT-OFF DETERMINATION 
 
The obtained 3-parameter model was used to plot experimental relative to calculated estimates of Gbinding as per Fig. 
27. A stringent score cut-off of -9.0 is expected to provide minimal false-positives while capturing most true high affinity 
binders. 
Figure 27. Experimental versus calculated estimates of Gbinding relative to ligands of the training set. 
 
2.5  FRAGMENT-BASED LIBRARY DOCKING 
 
2.5.1 MOTIVATION AND PROTOCOL 
The objective of identifying ligands including a moiety binding to Asn767 with high binding affinity indicates the suitability 
of fragment-based docking to the pocket of this target residue, notably as implemented in the ALTA procedure [51] (Fig. 
11).  
 
2.5.2 FRAGMENT LIBRARY GENERATION 
The ALTA procedure commences with a library of fragments defined as low molecular weight compounds with minimal 
rotatable bonds. The ZINC [53] lead-like library of near 4 million compounds (Mw< 350 g/mol, Nrot ≤ 7) was accordingly 
decomposed with DAIM [51] and filtered for fragments containing at least one hydrogen bond donor or acceptor, thus 
obtaining a library of 108’000 fragments. Characteristics of this fragment library are given in Fig. 28. 
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Figure 28. Fragment library characteristics 
 
 
2.5.3 FRAGMENT DOCKING, RANKING AND SELECTION 
Fragments were docked to each of three protein structures (2 MD-generated structures discussed previously and PDB 
structure 1UK0) using SEED [54,55] based on the polar docking vectors of Asn767 with 36 rotations around each docking 
vector and accurate calculation of SEED energy terms: van der Waals interactions and electrostatic energy with 
continuum solvation. A SEED total energy cut-off of -5 kcal/mol was applied to the top-ranked pose of each fragment; 
the resulting set of fragments were then ordered by their median rank across six terms: electrostatic difference, transfer 
energy, total energy, total energy efficiency (total energy/heavy atom count), van der Waals efficiency (van der Waals 
energy/heavy atom count) and electrostatic efficiency (electrostatic energy/heavy atom count) [56]. A total of 50 
fragments were selected (a subset of which are given in Fig. 30) relative to which a substructure search of the ZINC all 
purchasable library of 19 million compounds was performed with RDKIT [57]. It is of note that the fragments selected by 
each of the three protein conformations were largely unique (Fig. 29). 
Figure 29. Uniqueness of fragments binding to Asn767 discovered by SEED 
MD Basin I
89 unique
compounds
PDB 1UK0
584 unique 
compounds
MD Basin II
58 unique 
compounds
22 14
1
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2.5.4 FRAGMENT-CONTAINING LIGAND LIBRARY DOCKING AND SELECTION 
The substructure search lead to a library of near 800’000 compounds. Compounds of this library were protonated relative 
to a pH of 7 using obabel [58]. These were docked to the protein conformations relative to which the respective fragments 
were selected using VINA [48] to generate 20 poses per compound with filtering for a hydrogen bond to Asn767 and at 
least one further hydrogen around the nicotinamide binding site [59]. Issued poses were then filtered for reproduction 
of the anchor fragment binding mode by the corresponding compound moiety using RDKIT (RMSD of fragment to 
compound moiety of less than or equal to 3 Å) prior to minimisation with CHARMM (performed as described 2.4.2) and 
scoring (as per 2.4.3).   
Figure 30. Selection of fragments binding to Asn767 discovered by SEED  
With residue numbering shifted by -661 
 
 
2.5.5 SUMMARY OF SELECTED LIGANDS 
A total of 350 unique compounds passed the scoring cut-off. Two example compounds with their overlaid anchor 
fragment poses from SEED are given in Fig. 31. A subset of these compounds is currently under evaluation of binding 
affinity to ARTD-1 with an external service provider. Potent compounds will thereafter be evaluated for selectivity on 
ARTD-2.  
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Figure 31. Putative selective ligands of ARTD-1 identified with the ALTA procedure;  
a) shows a ligand (cyan) selected relative to the protein conformation of PDB 1UK0 overlapped with its anchor identified by fragment 
docking, b) shows another ligand docked into MD-generated protein conformation from Basin II. 
 
 
2.6  NICOTINAMIDE-MIMIC LIBRARY DOCKING 
 
 
2.6.1 MOTIVATION AND PROTOCOL 
Fragment binding to the nicotinamide binding site contribute highly to binding affinity. Indeed, a number of low molecular 
weight ligands binding uniquely at this site have low micromolar binding affinities [19,60]. As any ligand providing 
selective binding to Asn767 of ARTD-1 should also be potent, a library of compounds comprising such moieties was 
assembled. These moieties also provide the advantage of characteristic binding modes allowing reasoned selection of 
putative binding poses following docking.  
Figure 32. Structural requirements for potent ARTD-1 inhibitors from [61]  
showing interactions at the nicotinamide binding site 
 
 
 
 
 
 
 
a) b)
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Y907
N767
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2.6.2 NICOTINAMIDE-MIMIC LIBRARY GENERATION 
Known nicotinamide binding site moieties were assemble from the literature and are summarised in Fig. 33 [61-65]. These 
moieties were used to perform a substructure search of the eMolecules database [66] with the requirement that the 
characteristic NH group of Fig. 33 not be replaced by a heavy atom in the selected ligands. This resulted in a library of 
near 30’000 compounds. Compounds of the library were protonated relative to a pH of 7 using obabel [58]. 
 
Figure 33. Fragments reported to bind the nicotinamide binding site used for substructure searching 
 
2.6.3 LIGAND DOCKING AND SELECTION 
Ligands were docked to the four protein conformations of 2.3.3 using VINA [48] to generate 20 poses per compound, 
with filtering for a hydrogen bond to Asn767 and at least one further hydrogen bond to the nicotinamide binding site. 
Filtered poses were then minimised with CHARMM (as per 2.4.2), with scoring and application of the scoring cut-off 
resulting in 141 unique compounds. These were then clustered based on the following classes of moieties interacting 
with Asn767 with examples given in Fig. 34: a) conjugated amides including benzamides (14 compounds), b) pyridines (4 
compounds), c) methoxyphenyls (24 compounds), d) 5-membered heterocycles comprising N-0 ring atoms oriented 
towards Asn767 (16 compounds), e) nitriles (3 compounds), f) non-conjugated amides (4 compounds), g) sulfones and 
sulfonamides (7 compounds), h) carboxylates (5 compounds), i) non-conjugated ethers including cyclic ethers (6 
compounds), j) conjugated ethers including furans and dioxolanes (9 compounds), k) 5-membered heterocycles 
containing N-N oriented towards Asn767, including triazoles (4 compounds), as well as N-S 5-membered heterocycles, 
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pyrroles and anilines. Selected ligands from the different moiety classes are currently undergoing evaluation at an 
external service provider.  
 
Figure 34. Selected ligands from
the nicotinamide library classed
by fragment interacting with
Asn767. Fragments of the class
are represented as thick bonds
with hydrogen bonds to Asn767
indicated by dashed lines.
a) b) c)
d) e) f)
g) h) i)
j) k)
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2.7  DISCUSSION 
In silico methods may provide particular advantages over their purely experimental counterparts in the search for novel 
compounds forming interactions with particular residues or subsites of a target protein. Indeed, their atomic level 
tailoring allows rational selection of compounds prior to experimental validation. In particular, fragment-based 
approaches such as ALTA can be used to identify anchor fragments binding with high affinity to a target site.  
In the present study, two approaches were used to identify fragments and compounds binding to a new residue identified 
a basis for potential selective interactions with ARTD-1 relative to ARTD-2, namely a fragment-based approach and a 
tailored library approach. Each one provided a series of moieties and molecules containing these moieties.  
Molecular dynamics was used before docking to establish the accessibility of binding site residues as well as differential 
accessibility of equivalent residues between ARTD-1 and ARTD-2. This critical information is not yet available by other 
techniques, in which the dynamic aspects of protein binding sites are often observed only once inhibitors stabilising 
alternative protein conformations are at hand. As per McCammon’s [67] statement that “[v]irtual screening results are 
influenced by the PDB structure chosen for screening because the fit of individual ligands in the pocket is affected by 
even the most minor structural changes”, we found that small changes in protein conformation strongly influenced 
selected fragments and ligands passing a set cut-off. This underlines the importance of including a variety of protein 
structures in a high-throughput docking campaign. 
 
2.8  CONCLUSIONS 
The ligands proposed as putative high-affinity binders of ARTD-1 that are selective over ARTD-2 are currently undergoing 
experimental validation. The results will form the basis of follow-up studies, including crystal structure validation of in 
silico generated binding modes, offering insights into the use of molecular dynamics to identify binding-site accessible 
residues and novel protein conformations of relevance to high-throughput screening. Any such promising ligands will be 
considered for further development as potential tool or therapeutic compounds.  
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3. REPURPOSING APPROVED DRUGS AND SAFE INHIBITOR 
 
3.1 INTRODUCTION 
 
3.1.1 REPURPOSING MOTIVATION 
 
Sir James Black (1988 Nobel Laureate in Physiology and Medicine) has stated that “[t]he most fruitful basis for the 
discovery of a new drug is to start with an old drug” [1]. Indeed, not only may a given target biomolecule be implicated 
in more than one disease, but further drug compounds may bind with high potency to more than one target; of these, 
targets beyond those originally intended may be relevant to the efficacy of a compound in the context of the disease 
indication of original development, as well as in further diseases.  
Given the time and costs required to reach approval by authorities such as the US Food and Drug Administration (FDA) 
or European Medicines Agency (EMA), and even to pass through the stages of clinical development, repurposing of 
compounds found to be safe in humans has the potential to greatly increase the efficacy of the drug development 
process. Repurposing has already proven successful: as an example, thalidomide is efficacious in the treatment of both 
leprosy and multiple myeloma [2]. Recently, a complex network approach was used to analyse FDA-approved drugs to 
hundreds of protein targets, and 23 new drug-target associations were discovered [3], suggesting that this approach to 
drug finding is likely to meet with success. 
 
 
3.1.2 PROJECT OBJECTIVES 
 
Capitalising on the scoring function and protocol of the previous Chapter, two drug libraries were docked to ARTD-1: one 
containing FDA-approved compounds and second corresponding to literature-reported protein kinase inhibitors having 
successfully passed phase I of clinical trials in humans. The objective was to find compounds from these libraries binding 
to ARTD-1 with high putative binding affinity. 
 
 
3.2 COMPOUND LIBRARIES 
 
3.2.1 FDA-APPROVED COMPOUNDS 
FDA approved compounds have passed a series of evaluations of their safety. The FDA-approved subset of 3’176 
compounds was downloaded from the ZINC database [4]. Compounds of the library were protonated relative to a pH of 
7 using obabel [5]. 
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3.2.2 POST-CLINICAL TRIALS PHASE I KINASE INHIBITORS 
The ATP substrate of protein kinases shares a number of common chemical moieties with the NAD+ substrate of ARTD-1. 
For this reason, it was hypothesized that ATP-competitive inhibitors of protein kinases might also bind the ARTD-1 
substrate binding pocket. Over 100 small-molecule ATP-competitive inhibitors of protein kinases have passed the first 
phase of clinical trials and thus have acceptable toxicity profiles over a reasonable dose range. These protein kinase 
inhibitors were assemble from a thorough review of the literature [6-17], target-based queries of the PubChem Substance 
and Compound database [18] and DrugBank [19], as well as through searches of the U.S. National Institutes of Health 
Clinical Trials database [18]. In total, the assembled library contained 119 compounds which were protonated relative to 
a pH of 7 using obabel [5]. 
 
 
3.3 DOCKING TO ARTD-1 
 
3.3.1 PROTOCOL 
Ligands of each library were docked to the binding site of four protein conformations of ARTD-1 (2 crystal structures and 
2 MD-generated conformations as per 2.3.3) using VINA [20] to generate 20 poses per ligand, with filtering for at least 
one hydrogen bond around the nicotinamide binding site. Docked poses were minimised with CHARMM [21] (by the 
iterative steepest descent method for 500 steps followed by the conjugate gradient method for 10’000 steps), allowing 
residues with atoms within 5 Å of the ligand to remain flexible along with the ligand during minimisation. Protein atoms 
were parametrised with CHARMM27 parameters while ligands were parametrised according to the CHARMM General 
Force Field [22] with MATCH [23]. The scoring function and cut-off of 2.4.3 and 2.4.4 were applied, with evaluation of 
terms as per 2.4.2. 
 
 
3.3.2 RESULTS AND SELECTED COMPOUNDS 
 
Of the original 3’176 compounds forming the FDA-approved compound library, 202 unique compounds met the hydrogen 
bonding requirements and passed the scoring function cut-off. These were visually inspected and 13 compounds (0.04% 
of the original library) were selected for experimental validation. These are listed in panel b) of Figure 35, along with their 
indication of origin, and an example docked pose in panel a). 
The post-clinical trials phase I library of kinase inhibitors issued 11 compounds, representing 9% of the original library, 
selected for experimental validation. These are listed in panel b) of Figure 36, along with their target of origin and an 
example docked pose in panel a). 
Selected compounds are currently undergoing evaluation at an external service provider.  
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Figure 35. FDA-approved compounds putatively binding ARTD-1 with high affinity: a) docked pose of mesuximide in the MD-
generated protein conformation of Basin II (see 2.3.3), b) list of selected compounds for affinity evaluation, with indication of origin 
Figure 36. Post-clinical trials phase I kinase inhibitor compounds putatively binding ARTD-1 with high affinity: a) docked pose of 
nilotinib in the MD-generated protein conformation of Basin I (see 2.3.3), b) list of selected compounds for affinity evaluation, with 
protein kinase target of origin 
 
 
3.4 CONCLUSIONS 
 
An effective docking protocol and scoring function has been coupled with an in silico screening of known non-toxic 
compounds. This approach offers an efficient means to repurpose highly-developed compounds quickly and at low cost. 
Further, it may offer insights into new binding partners of potential relevance to compound efficacy in the context of the 
disease indication of origin and in the treatment of new indications. 
  
b)
Mesuximide: epilepsy
Sylibinin: cancer 
Citalopram: depression
Sparfloxacin: bacterial infection
Ziprasidone: schizophrenia
Olopatadine: antihistamine
Flubendazole: anti-parasitic
Fenspiride: anti-inflammatory
Piperacetazine: anti-psychotic
Troxipide: anti-convulsant
Tiagabine: migraine
Estropitate: menopause
Danazol: endometriosis
Y907
S904
G863
a)
b)
Telatinib: VEGFR
Tofacitinib: JAK3
Tozasertibe: Aurora kinases
AZD-7762: Checkpoint kinases
Brivanib: VEGFR
Motesanib: VEGFR
Nilotinib: Multiple kinases
OSI-906: IGFR
Pelitinib: ERBB
PI-103: PI3K
SU-6668: FGFR
a)
Y907
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